NPM1 and acute myeloid leukemia: In this regard, a multicenter Phase 2 study to establish the efficacy of dactinomycin 12.5 μg/Kg/day for 5 days in NPM1-mutated AML patients unfit or relapsed after hypomethylating agents (HMAs) is currently ongoing (EudraCT n.2014-003490-41).